Home » Stocks » CUE

Cue Biopharma, Inc. (CUE)

Stock Price: $10.42 USD -0.21 (-1.98%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 344.60M
Revenue (ttm) 3.81M
Net Income (ttm) -44.47M
Shares Out 30.43M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $10.42
Previous Close $10.63
Change ($) -0.21
Change (%) -1.98%
Day's Open 10.49
Day's Range 10.17 - 10.63
Day's Volume 117,800
52-Week Range 9.87 - 22.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 hours ago - Zacks Investment Research

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage a...

2 months ago - GlobeNewsWire

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow...

2 months ago - Zacks Investment Research

Cue Biopharma Inc (NASDAQ: CUE) has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive re...

2 months ago - Benzinga

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on In...

Other stocks mentioned: APOP, CKX, ELTK, LEDS, OBLN, PRPO, PTE ...
2 months ago - InvestorPlace

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selective...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selective...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selective...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selective...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

5 months ago - GlobeNewsWire

Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs

5 months ago - GlobeNewsWire

Insider buying is often a profitable signal for bulls. Insiders only buy for one reason: they believe their company's stock is going higher.

Other stocks mentioned: GNTY, HCDI, LNDC, PSXP, RILY, VGR
6 months ago - InvestorPlace

Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells. Cue Biopharma has expanded its pipeline to include 7 therapeutics with 1 undergoi...

6 months ago - Seeking Alpha

Investors need to pay close attention to Cue Biopharma (CUE) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage ...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage ...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage ...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage ...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage ...

9 months ago - GlobeNewsWire

Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development

10 months ago - GlobeNewsWire

Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity

10 months ago - GlobeNewsWire

Cue Biopharma (CUE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively en...

10 months ago - GlobeNewsWire

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively eng...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively eng...

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively eng...

11 months ago - GlobeNewsWire

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to select...

1 year ago - GlobeNewsWire

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at A...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to select...

1 year ago - GlobeNewsWire

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively enga...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively enga...

1 year ago - GlobeNewsWire

Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series

1 year ago - GlobeNewsWire

Dynamic New Players Gain Momentum In Digital, Data And Patient-Centric Space

Other stocks mentioned: EVBG, FVRR
1 year ago - Seeking Alpha

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: LVGO, SMED, THMO, VNET
1 year ago - Zacks Investment Research

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.

Other stocks mentioned: ATXI, GAIA, PJT, SPTN
1 year ago - Zacks Investment Research

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Cue Biopharma (CUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

Cue Biopharma: An Innovative But Risky Immunology Pick For 2020

1 year ago - Seeking Alpha

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: FFIN, FMNB, HONE, IBCP
1 year ago - Zacks Investment Research

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 2, 2018
CEO
Daniel Passeri
Employees
50
Stock Exchange
NASDAQ
Ticker Symbol
CUE
Full Company Profile

Financial Performance

In 2020, Cue Biopharma's revenue was $3.15 million, a decrease of -8.79% compared to the previous year's $3.46 million. Losses were -$44.78 million, 22.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Cue Biopharma stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 187.91% from the latest price.

Price Target
$30.00
(187.91% upside)
Analyst Consensus: Strong Buy